Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Electronic Spectacles Versus Low Dose Atropine in Young Myopes

NCT06034379 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Kubota Vision Inc
Phase
Not applicable
Started
2023-10-01
Last updated
2024-12-12

Condition(s) studied

Myopia

Investigational drug(s) / intervention(s)

eSpectacle Clinical prototype (CP1) device0.01% atropine →

eSpectacle Clinical prototype (CP1) device: The CP1 device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights of approximately 4800 nits illumination to the peripheral retina.

0.01% atropine: Atropine is a and anticholinergic medication which can be used for dilation and cycloplegia.

Study summary

This is a bilateral, dispensing, masked, randomized clinical trial. Myopic children will be randomly assigned to one of the following: (1) Investigational clinical prototype (CP1) device without atropine, (2) Investigational CP1 device with daily instillation of 0.01% atropine, or (3) daily instillation of 0.01% atropine without use of the investigational CP1 device. Primary endpoint: Difference in the 12-month change of cycloplegic spherical refractive error and axial length between each of the three treatment groups.

Eligibility

Sex
ALL
Min age
6 Years
Max age
13 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. The subject must be between 6 and 13 years of age (inclusive). 2. The subject must appear able and willing to adhere to the instructions set forth in the clinical protocol. 3. The guardian of a minor under 18 years old must read and sign the STATEMENT OF INFORMED CONSENT and be provided a copy of the form. The subject under 18 years old must be willing to assent to the STATEMENT OF INFORMED CONSENT. 4. Spherical component of refraction in the range of -0.50 to -10.00 DS in each eye. 5. Refractive cylinder less than or equal to 2.00 DC in each eye (minus cylinder format). 6. Best corrected distance VA of at least 20/25 in each eye. Exclusion Criteria: 1. Currently pregnant or lactating 2. History of severe dry eye, strabismus, or amblyopia 3. Any systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g., diabetes, rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with the participation in the study at the investigator's discretion. 4. Use of systemic or ocular medications (e.g., chronic steroid use) that are known to interfere with vision and ocular accommodation at the investigator's discretion. 5. Any previous, or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK, strabismus surgery etc.) or orthokeratology 6. Any active ocular infection. 7. Any accommodative or binocular anomalies including amblyopia. 8. Any physical or mental developmental delay. 9. Any relevant ocular or systemic condition deemed unacceptable by the investigator that may negatively impact the subject's performance or ability to successfully complete the study (at the investigator's discretion) 10. Anisometropia greater than 1.50D

Primary outcome measure(s)

  • CSER — 12 months
    Difference in the changes of cycloplegic spherical refractive error between each of the three treatment groups.
  • AL — 12 months
    Difference in the changes of axial length between each of the three treatment groups.

Trial sites (1)

FacilityCityRegionStatus
CMU Hsinchu Hospital Hsinchu Taiwan Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06034379 on ClinicalTrials.gov ↗ ← All trials in Taiwan